Literature DB >> 28835125

Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution.

Dirk Grimm1,2,3, Hildegard Büning4,5,6,7.   

Abstract

Recombinant gene delivery vectors derived from naturally occurring or genetically engineered adeno-associated viruses (AAV) have taken center stage in human gene therapy, fueled by rapidly accumulating and highly encouraging clinical data. Nonetheless, it has also become evident that the current generation of AAV vectors will require improvements in transduction potency, antibody evasion, and cell specificity in order to realize their full potential and to widen applicability in larger patient cohorts. Fortunately, in the recent past, the field has seen a flurry of exciting new developments that enhance our understanding of AAV vector biology, including virus-host interactions, and/or that expand our arsenal of technologies for AAV capsid design and evolution. This review highlights a collection of latest advances in these areas, which, in the authors' opinion, hold particular promise to propel the AAV vector field forward in the near future, especially when applied in combination. These include fundamental novel insights into the AAV life cycle, from an unexpected role of autophagy and interactions with other viruses to the (re-)discovery of a universal AAV receptor and the function of AAV-AAP for capsid assembly. Concurrently, recent successes in the rational design of next-generation synthetic AAV capsids are pointed out, exemplified by the structure-guided derivation of AAV mutants displaying robust in vivo immune evasion. Finally, a variety of new and innovative strategies for high-throughput generation and screening of AAV capsid libraries are briefly reviewed, including Cre recombinase-based selection, ancestral AAV capsid reconstruction, and DNA barcoding of AAV genomes. All of these examples showcase the present momentum in the AAV field and, together with work by many other academic or industrial entities, raise substantial optimism that the remaining hurdles for human gene therapy with AAV vectors will (soon) be overcome.

Entities:  

Keywords:  AAV; adeno-associated virus; immune escape; molecular evolution; virus engineering; virus–host interaction

Mesh:

Substances:

Year:  2017        PMID: 28835125     DOI: 10.1089/hum.2017.172

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  49 in total

1.  Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy.

Authors:  Umut Cagin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Gene therapy for inherited arrhythmias.

Authors:  Vassilios J Bezzerides; Maksymilian Prondzynski; Lucie Carrier; William T Pu
Journal:  Cardiovasc Res       Date:  2020-07-15       Impact factor: 10.787

Review 3.  Adeno-associated virus-based Alzheimer's disease mouse models and potential new therapeutic avenues.

Authors:  Lars M Ittner; Matthias Klugmann; Yazi D Ke
Journal:  Br J Pharmacol       Date:  2019-04-23       Impact factor: 8.739

4.  Nonhuman Primate Optogenetics: Current Status and Future Prospects.

Authors:  Ken-Ichi Inoue; Masayuki Matsumoto; Masahiko Takada
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  In vivo functional screening for systems-level integrative cancer genomics.

Authors:  Julia Weber; Christian J Braun; Dieter Saur; Roland Rad
Journal:  Nat Rev Cancer       Date:  2020-07-07       Impact factor: 60.716

6.  An Engineered Galactosylceramidase Construct Improves AAV Gene Therapy for Krabbe Disease in Twitcher Mice.

Authors:  Xiufang Pan; Scott A Sands; Yongping Yue; Keqing Zhang; Steven M LeVine; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2019-07-18       Impact factor: 5.695

7.  The Influence of Murine Genetic Background in Adeno-Associated Virus Transduction of the Mouse Brain.

Authors:  Ting He; Michelle S Itano; Lauriel F Earley; Nikita E Hall; Natallia Riddick; R Jude Samulski; Chengwen Li
Journal:  Hum Gene Ther Clin Dev       Date:  2019-12       Impact factor: 5.032

8.  Primate optogenetics: Progress and prognosis.

Authors:  Yasmine El-Shamayleh; Gregory D Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-23       Impact factor: 11.205

9.  Adeno-Associated Virus Genome Interactions Important for Vector Production and Transduction.

Authors:  Anna C Maurer; Matthew D Weitzman
Journal:  Hum Gene Ther       Date:  2020-05       Impact factor: 5.695

Review 10.  In vivo epigenome editing and transcriptional modulation using CRISPR technology.

Authors:  Cia-Hin Lau; Yousin Suh
Journal:  Transgenic Res       Date:  2018-10-04       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.